Conexxence (denosoumab)
Numéro de dossier de l’APP:
23491
État des négociations:
En négociation
Indication(s):
• treatment of postmenopausal women with osteoporosis at high risk for fracture;
• treatment to increase bone mass in men with osteoporosis at high risk for fracture;
• treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture;
• treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and
• treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture
• treatment to increase bone mass in men with osteoporosis at high risk for fracture;
• treatment to increase bone mass in men with nonmetastatic prostate cancer receiving androgen deprivation therapy, who are at high risk for fracture;
• treatment to increase bone mass in women receiving adjuvant aromatase inhibitor therapy for nonmetastatic breast cancer; and
• treatment to increase bone mass for the treatment and prevention of glucocorticoid- induced osteoporosis in women and men at high risk for fracture
Promoteur/fabricant:
Fresenius Kabi Canada Ltd.
Numéro de projet de l’AMC:
Sans objet
Lettre d’entente de l’APP:
Conclusion du processus de négociation:
Sans objet